Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Keyword: Oral Administration

Publisher: GlobeNewswire

Published: May 29, 2026

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee… [+4177 chars]

Read Full Story ↗

Related Content

Related Story Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies

GlobeNewswire
Related Story Mitochondrial oxidative phosphorylation inhibition by 9α,11α-dihydroxy-kaurenoic acid promotes ROS-associated apoptosis and suppresses cancer stemness in non-small cell lung cancer

Nature.com
Related Story GSC Products, LLC - 729653 - 05/18/2026

FDA.gov